Welcome to Markets Desk, here's what's moving the needle this hour.
Bristol Myers Squibb is trading below ten times forward earnings, and the market is asking whether that discount is a value trap or a genuine opportunity. The answer hinges on patent cliffs — two blockbuster drugs are set to lose exclusivity, and without a credible pipeline to fill that revenue gap, the valuation may be cheap for a reason. Investors should tread carefully.
Shifting to the labor market, a quiet structural shift is underway in how companies are deploying entry-level talent. Rather than building foundational skills, young workers are increasingly being assigned to monitor and correct AI outputs — a role that looks promising on paper but offers little in the way of career progression or transferable expertise. Economists and workforce analysts are raising flags about what this means for the next generation of skilled labor.
And on the trade and manufacturing front, Audi's parent company Volkswagen is committing four point two billion dollars to build a new automobile plant in Georgia. The announcement carries obvious political weight, but the underlying economics matter too — it signals that European automakers are recalibrating supply chains and betting on American production capacity amid ongoing tariff uncertainty and shifting demand for electric vehicles.
That's the tape. Markets Desk, signing off the floor.
